Compound Evidence File
#EC-2026-0873
DHB (1-Test Cyp) Oral
Filed under Oral Tablets. The bureau holds 147 laboratory returns for this compound from 59 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
59 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 28 Dec 2025 | 6 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 9 May 2026 | 11 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Mar 2026 | 17 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Jan 2026 | 8 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Nov 2025 | 21 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 13 Feb 2026 | 5 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 18 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 26 Feb 2026 | 8 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 8 Mar 2026 | 3 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Aug 2026 | 14 Aug 2026 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 10.0 | 10.0 | 10.0 | 6 May 2025 | 6 May 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 9.9 | 14 Jan 2026 | 10 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Jun 2026 | 15 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Mar 2026 | 19 May 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 22 May 2026 | 3 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 1 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 8 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 9.9 | 9.9 | 10.0 | 12 Jan 2026 | 5 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 6 Jul 2026 | 6 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 9.9 | 3 May 2026 | 5 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Jan 2026 | 20 Jan 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 24 Feb 2026 | 15 Apr 2026 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 9.9 | 9.9 | 9.9 | 9 Jun 2025 | 9 Jun 2025 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 9.1 | 9.1 | 9.1 | 14 Jan 2025 | 14 Jan 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 8.8 | 7.4 | 9.5 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.7 | 6.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 8.7 | 8.7 | 8.7 | 21 May 2025 | 21 May 2025 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 8.1 | 8.1 | 8.1 | 25 Apr 2025 | 25 Apr 2025 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 7.8 | 7.8 | 7.8 | 6 May 2025 | 6 May 2025 |
| Peptide PartnersCASE #VI-2026-0295 | X | 1 | 7.7 | 7.7 | 7.7 | 13 Jun 2025 | 13 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 7.5 | 6.0 | 8.6 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 7.5 | 7.2 | 7.8 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 7.4 | 6.5 | 8.9 | 24 May 2026 | 24 May 2026 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 7.4 | 7.4 | 7.4 | 20 Jun 2025 | 20 Jun 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 2 | 7.2 | 6.0 | 8.3 | 27 Feb 2025 | 21 May 2026 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | X | 1 | 7.2 | 7.2 | 7.2 | 13 Feb 2025 | 13 Feb 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 7.1 | 7.1 | 7.1 | 24 Apr 2025 | 24 Apr 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 7.0 | 5.7 | 8.3 | 8 Jul 2025 | 25 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | X | 6 | 6.8 | 4.8 | 8.4 | 3 Jun 2025 | 24 May 2026 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 3 | 6.7 | 5.7 | 7.4 | 6 May 2025 | 24 May 2026 |
| Peptide CraftersCASE #VI-2026-0994 | X | 2 | 6.7 | 6.4 | 7.0 | 14 Jan 2025 | 21 May 2026 |
| ZhuoYan labCASE #VI-2026-0902 | X | 3 | 6.4 | 4.3 | 8.5 | 17 Dec 2024 | 17 May 2026 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 6.3 | 6.3 | 6.3 | 16 Mar 2025 | 16 Mar 2025 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 1 | 6.2 | 6.2 | 6.2 | 7 May 2025 | 7 May 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 5.9 | 5.9 | 5.9 | 11 Jun 2025 | 11 Jun 2025 |
| OupeptideCASE #VI-2026-0435 | X | 4 | 5.6 | 3.6 | 6.5 | 27 Feb 2025 | 26 Jan 2026 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 5.5 | 5.5 | 5.5 | 13 Feb 2025 | 13 Feb 2025 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 5.0 | 5.0 | 5.0 | 7 May 2025 | 7 May 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 4.2 | 4.2 | 4.2 | 2 Jul 2025 | 2 Jul 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 4.1 | 4.1 | 4.1 | 9 Jun 2025 | 9 Jun 2025 |
| Peptides For SaleCASE #VI-2026-0614 | X | 2 | 3.9 | 2.7 | 5.1 | 9 Jun 2025 | 26 Jan 2026 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 2.9 | 2.9 | 2.9 | 13 Feb 2025 | 13 Feb 2025 |
| Zhuoyue BiotechnologyCASE #VI-2026-0632 | X | 1 | 1.1 | 1.1 | 1.1 | 3 Jul 2025 | 3 Jul 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.7 | 0.7 | 0.7 | 2 Apr 2025 | 2 Apr 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 17 Dec 2024 | 17 Dec 2024 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 0.0 | 0.0 | 0.0 | 11 Jun 2025 | 11 Jun 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for DHB (1-Test Cyp) Oral alone.